Key hire
Aravax Pty Ltd announces opening of IND for Phase 2 clinical trials of PVX108, a next-generation immunotherapy for the treatment of peanut allergy
Aravax clears its US FDA application to trial its peanut-allergy immunotherapy PVX108 in Phase 2 studies across two countries, and adds a prominent food-allergy paediatric specialist to its scientific advisory board.